摘要
目的探讨黄芩汤联合西药治疗小儿溃疡性结肠炎的临床疗效。方法选取龙游县人民医院2020年1月至2022年1月收治的小儿溃疡性结肠炎患儿100例进行病例对照研究,根据治疗方法不同分为对照组(n=50)、观察组(n=50),对照组给予常规西药治疗,观察组在对照组基础上给予黄芩汤治疗,两组治疗14 d。比较两组治疗前后中医证候积分、临床疗效、炎症指标水平、肠黏膜改善评分、不良反应发生率。结果治疗后,观察组中医证候评分降低程度明显高于对照组(P<0.05);观察组总有效率为98%(49/50),高于对照组的82%(41/50)(χ^(2)=7.11,P<0.05);观察组肿瘤坏死因子α、白细胞介素6、C反应蛋白分别为(12.83±4.53)ng/L、(8.55±1.44)ng/L、(6.35±0.99)mg/L,均低于对照组的(24.41±5.38)ng/L、(13.14±1.51)ng/L、(10.03±1.05)mg/L(t=13.21、7.52、5.15,均P<0.05);观察组改良的Baron评分中溃疡[(1.43±0.20)分]、充血[(1.24±0.27)分]、糜烂[(1.36±0.34)分]、水肿[(1.02±0.21)分]评分改善情况均明显优于对照组[(2.48±0.52)分、(2.19±0.37)分、(2.45±0.32)分、(2.35±0.40)分](t=5.12、4.52、3.73、4.84,均P<0.05);观察组不良反应发生率为4%(2/50),低于对照组的18%(9/50)(χ^(2)=5.01,P<0.05)。结论对溃疡性结肠炎患儿采用黄芩汤联合西药治疗,可有效改善中医证候评分、肠黏膜评分,不良反应发生率低,临床效果较好,安全性高。
Objective To investigate the clinical efficacy of Huangqin decoction combined with western medicine in the treatment of pediatric ulcerative colitis.Methods A total of 100 children with ulcerative colitis who received treatment at the Longyou People's Hospital from January 2020 to January 2022 were included in this case-control study.They were divided into a control group(n=50)and an observation group(n=50)according to different treatment methods.Children in the control group were treated with routine western medicine,while those in the observation group were treated with routine western medicine plus Huangqin decoction.Both groups of children were treated for 14 days.The two groups of children were compared in terms of traditional Chinese medicine syndrome score,clinical efficacy,inflammatory factor levels,intestinal mucosal improvement score,and incidence of adverse reactions.Results After treatment,the level of decrease in traditional Chinese medicine syndrome score in the observation group was significantly greater than that in the control group(P<0.05).The total response rate in the observation group was 98%(49/50),which was significantly higher than that in the control group[82%(41/50),χ^(2)=7.11,P<0.05].The levels of tumor necrosis factorα,interleukin-6,and C-reactive protein in the observation group were(12.83±4.53)ng/L,(8.55±1.44)ng/L,and(6.35±0.99)mg/L,respectively,which were significantly lower than those in the control group[(24.41±5.38)ng/L,(13.14±1.51)ng/L,(10.03±1.05)mg/L,t=13.21,7.52,5.15,all P<0.05].The improvement scores for ulcer,congestion,erosion,and edema in the observation group were(1.43±0.20)points,(1.24±0.27)points,(1.36±0.34)points,and(1.02±0.21)points,respectively,which were significantly better than those in the control group[(2.48±0.52)points,(2.19±0.37)points,(2.45±0.32)points,and(2.35±0.40)points,t=5.12,4.52,3.73,4.84,all P<0.05].The incidence of adverse reactions in the observation group was 4%(2/50),which was significantly lower than that in the control group[18%(
作者
郁银娟
邱根祥
吴绵勇
Yu Yinjuan;Qiu Genxiang;Wu Mianyong(Department of Pediatrics,Longyou People's Hospital,Quzhou 324400,Zhejiang Province,China)
出处
《中国基层医药》
CAS
2024年第2期267-272,共6页
Chinese Journal of Primary Medicine and Pharmacy
关键词
结肠炎
溃疡性
医学
中国传统
炎症
肠黏膜
治疗结果
病人安全
儿童
Colitis,ulcerative
Medicine,Chinese traditional
Inflammation
Intestinal mucosa
Treatment outcome
Patient safety
Child
